3beta,7alpha,15alpha-trihydroxy-5-androsten-17-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 45092605 |
| SCHEMBL ID | 855786 |
| MeSH ID | M000600139 |
| Synonym |
|---|
| 2963-69-1 |
| SCHEMBL855786 |
| 3b,7a,15a-trihydroxyandrost-5-en-17-one |
| (3beta,7alpha,15alpha)-3,7,15-trihydroxy-androst-5-en-17-one |
| 3beta,7alpha,15alpha-trihydroxy-5-androsten-17-one |
| (3s,7s,8r,9s,10r,13s,14s,15s)-3,7,15-trihydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one |
| androst-5-en-17-one, 3,7,15-trihydroxy-, (3beta,7alpha,15alpha)- |
| DTXSID701036209 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||